Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Tumor environments sculpt diverse natural killer cells for cancer therapies

For decades, natural killer (NK) cells have been classified into two main groups based on surface markers: one specialized for cytokine production and the other for direct killing.

4 Sep 2026

Newly diagnosed AML patients benefit from less-intensive combination treatment

Investigators from the Mass General Brigham Cancer Institute have found that adults with newly diagnosed acute myeloid leukemia (AML) receiving a less-intensive combination of azacitidine and venetoclax had more than twice as much time before treatment failed, the leukemia returned or worsened, or they died, compared with patients receiving intensive chemotherapy.

2 Sep 2026

$15 million trial aims to improve treatment decisions for older AML patients

A newly funded national clinical trial initiative will gather critical evidence to determine the best treatment strategies for older adults with acute myeloid leukemia (AML), an aggressive, fast-moving blood cancer that leaves a substantial proportion of older patients facing uncertainty about whether to proceed to stem cell transplantation or continue non-transplant therapy.

27 Aug 2026

Protein degrader shows strong activity against treatment-resistant blood cancers

A first-in-class therapy to target MYC, one of the most sought-after and difficult targets in cancer biology, showed promise in hard-to-treat blood cancers, according to a new preclinical study from The University of Texas MD Anderson Cancer Center published in Blood.

24 Aug 2026

New study uncovers metabolic vulnerability in high-risk myelodysplastic syndromes

Researchers at the University of Colorado Anschutz Cancer Center have identified a previously unknown metabolic weakness in the stem cells that drive high-risk myelodysplastic syndromes (MDS), a discovery that could lead to more targeted treatments for this aggressive blood cancer.

10 Aug 2026

New gene signature predicts immunotherapy success for bone marrow cancers

A team led by researchers from the German Cancer Research Center (DKFZ), the HI-STEM Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital (UKHD) has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and, in principle, fight cancer cells, but is often not sufficiently activated.

10 Aug 2026

Researchers find a new genetic vulnerability in acute myeloid leukemia

A study published in Nature Cell Biology reports a new vulnerability in acute myeloid leukemia (AML) that might lead to novel therapies to treat this cancer while minimizing harm to normal cells.

7 Aug 2026

Experimental drug CS18 shows promise for overcoming cancer treatment resistance

Researchers at Baylor College of Medicine have developed a drug called CS18 that disrupts the ability of cancer cells to survive therapy. The findings, published in Science Advances, support exploring the possibility of using CS18 to treat human cancer in the future.

5 Aug 2026

New AI score enhances monitoring of myelodysplastic neoplasms

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.

20 Jul 2026

Researchers uncover new T cell attack mechanism against acute myeloid leukemia

Researchers at The University of Texas MD Anderson Cancer Center have discovered a new way in which T cells attack acute myeloid leukemia (AML) cells, which may help explain why AML is particularly sensitive to immune-based treatments and could guide the development of future cancer immunotherapies.

15 Jul 2026

New therapy targets Hippo pathway to fight treatment-resistant acute myeloid leukemia

Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy remained effective in treatment-resistant acute myeloid leukemia (AML) through activating the Hippo pathway, a tumor-suppressing pathway linked to cancer growth and drug resistance.

13 Jul 2026

Strategic collaboration funds interdisciplinary projects to improve cancer care

Rice University's Synthesis X Center and Houston Methodist Neal Cancer Center have awarded $90,000 in seed grants as part of a new strategic collaboration.

8 Jul 2026

Study explains how leukemia creates inflammatory lung environments

Acute myeloid leukemia (AML) does more than infiltrate the lungs: it also transforms lung tissue to create an inflammatory environment that promotes the expansion of tumor cells and impairs respiratory function.

30 Jun 2026

Study reveals how leukemia cells invade lungs and cause breathing problems

Led by NYU Langone Health researchers, a new study shows how blood cancer cells enter the lungs, damage tissue, and cause severe breathing problems.

29 Jun 2026

Gene fusion patterns refine classification of rare acute leukemias

Acute leukemias with chimeric fusion genes involving FET (FUS, EWSR1, and TAF15) family proteins and ETS (E26 transformation-specific)-like transcription factors often present with unique clinical and pathological characteristics.

27 Jun 2026

New all-oral regimen improves treatment convenience for AML patients

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment.

3 Jun 2026

Roswell Park scientists present five key cancer studies at clinical meeting

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago.

25 May 2026

Loss of X chromosome linked to female infertility risk

Chromosomes carry genetic information for biological sex, which generally assigns women two X chromosomes and men XY chromosomes.

12 May 2026

Diverse leukemia stem cells may drive AML relapse after therapy

Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML).

7 May 2026

From killers to strategists: CAR T cells enter their multifunctional era

A review of 1,801 registered CAR T clinical trials shows that multifunctional designs now account for 533 trials and 33% of new CAR T products submitted for clinical testing in 2025. The field is shifting toward multitargeted, safety-controlled, cytokine-secreting, and checkpoint-modulating CAR T cells, but manufacturing, regulation, and limited clinical outcome data remain key barriers.

30 Apr 2026